CO5700778A2 - Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular - Google Patents
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celularInfo
- Publication number
- CO5700778A2 CO5700778A2 CO05045078A CO05045078A CO5700778A2 CO 5700778 A2 CO5700778 A2 CO 5700778A2 CO 05045078 A CO05045078 A CO 05045078A CO 05045078 A CO05045078 A CO 05045078A CO 5700778 A2 CO5700778 A2 CO 5700778A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocyclic
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Abstract
1.- El uso de un compuesto de fórmula I y por lo menos un agente quimioterapéutico para el tratamiento del cáncer, en el cual el compuesto de fórmula I es como sigue: en el cual, cada R es, en forma independiente, hidrógeno, hidroxi, alquilo, arilo, cicloalquilo, heteroarilo, alcoxi, heterocíclico o amino;cada R1 es, en forma independiente, alquilo, halo, alcoxi, haloalquilo, haloalcoxi, cicloalquilo, heterocíclico, hidroxi, -C(O)-R8, -NR9R10, -NR9C(O)-R12 o -C(O)NR9R10;cada R2 es, en forma independiente, alquilo, arilo, heteroarilo, -C(O)-R8 o SO2R", donde R" es alquilo, arilo, heteroarilo, NR9N10 o alcoxi;cada R5 es, en forma independienle, hidrógeno, alquilo, arilo, haloalquilo, cicloalquilo, heteroarilo, heterocíclico, hidroxi, -C(O)-R8 o (CHR)rR11;X es O, o S;j es 0 ó 1;p es 0, 1, 2 ó 3;q es 0, 1 ó 2;r es 0, 1, 2 ó 3;R8 es hidroxi, alquilo, arilo, heteroarilo, alcoxi, cicloalquilo o heterocíclico;R9 y R10 son, en forma independiente, hidrógeno, alquilo, arilo, aminoalquilo, heteroarilo, cicloalquilo y heterocíclico, o R9 y R10 junto con N pueden formar un anillo, donde los átomos del anillo se seleccionan del grupo formado por C, N, o y S;R11 es hidroxi, amino, amino monosustituído, amino disustituido, alquilo, arilo, heteroarilo, alcoxi, cicloalquilo o heterocíclico R12 es alquilo, arilo, heteroarilo, alcoxi, cicloalquilo o heterocíclico; y Z es hidroxi, -O-alquilo, o -NR3R4, donde R3 y R4 son, en forma independiente, hidrógeno, alquilo, arilo, heteroarilo, cicloalquilo, o heterocíclico, o ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42638602P | 2002-11-15 | 2002-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5700778A2 true CO5700778A2 (es) | 2006-11-30 |
Family
ID=32326343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05045078A CO5700778A2 (es) | 2002-11-15 | 2005-05-11 | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040152759A1 (es) |
EP (1) | EP1562600A4 (es) |
JP (1) | JP2006508981A (es) |
KR (1) | KR20050086594A (es) |
CN (2) | CN100430060C (es) |
AR (1) | AR042042A1 (es) |
AU (1) | AU2003290943A1 (es) |
BR (1) | BR0315630A (es) |
CA (1) | CA2506308A1 (es) |
CO (1) | CO5700778A2 (es) |
GT (1) | GT200300245A (es) |
MX (1) | MXPA05005150A (es) |
NL (1) | NL1024779C2 (es) |
NO (1) | NO20052578L (es) |
PA (1) | PA8588601A1 (es) |
PE (1) | PE20040835A1 (es) |
PL (1) | PL376954A1 (es) |
RU (1) | RU2342140C2 (es) |
TW (1) | TW200418837A (es) |
UY (1) | UY28081A1 (es) |
WO (1) | WO2004045523A2 (es) |
ZA (1) | ZA200503841B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525324A (en) | 2000-10-20 | 2005-03-24 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
EP2301533A1 (en) * | 2004-07-09 | 2011-03-30 | University of Pittsburgh | Wortmannin Analogs and Method of Using Same |
WO2006030826A1 (ja) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
RU2007135167A (ru) * | 2005-03-23 | 2009-03-27 | Пфайзер Продактс Инк. (Us) | Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака |
RU2007141654A (ru) * | 2005-05-12 | 2009-05-20 | Пфайзер Инк. (US) | Противоопухолевая комбинированная терапия, в которой используется сунитиниб-малат |
US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
CN102716490A (zh) * | 2005-09-01 | 2012-10-10 | 卫材R&D管理有限公司 | 药物组合物的崩解性的改善方法 |
EP1934241B1 (en) * | 2005-09-15 | 2012-11-14 | Council of Scientific and Industrial Research | Novel series of imidazolyl substituted steroidal and indan-1-one derivatives |
BRPI0616202A2 (pt) * | 2005-09-20 | 2011-06-14 | Pfizer Prod Inc | formas de dosagem e uso de um inibidor da tirosina quinase |
CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
WO2007136103A1 (ja) * | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c-Abl特异性抑制剂的新用途 |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
JP2011510079A (ja) * | 2008-01-22 | 2011-03-31 | コンサート ファーマシューティカルズ インコーポレイテッド | ゲフィチニブ誘導体 |
MX2010008187A (es) * | 2008-01-29 | 2010-08-10 | Eisai R&D Man Co Ltd | Uso combinado de inhibidor de angiogenesis y taxano. |
JP2011526615A (ja) * | 2008-07-02 | 2011-10-13 | ジェネリクス・(ユーケー)・リミテッド | 3−ピロール置換2−インドリノン誘導体の調製 |
US20100143295A1 (en) * | 2008-12-05 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Quinazoline inhibitors of egfr tyrosine kinase |
CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
US9931313B2 (en) * | 2012-04-04 | 2018-04-03 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
TWI721954B (zh) | 2014-08-28 | 2021-03-21 | 日商衛材R&D企管股份有限公司 | 高純度喹啉衍生物及其生產方法 |
SI3263106T1 (sl) | 2015-02-25 | 2024-02-29 | Eisai R&D Management Co., Ltd. | Postopek zatiranja grenkobe derivata kinolina |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
ES2906356T3 (es) * | 2016-06-09 | 2022-04-18 | Yuki Gosei Yakuhin Kogyo Kk | Método para preparar 4-(piperidin-4-il)morfolina |
CN114585389A (zh) * | 2019-09-26 | 2022-06-03 | 星法马私人有限公司 | 治疗性树枝状大分子 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395734B1 (en) * | 1998-05-29 | 2002-05-28 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
AU1928501A (en) * | 1999-11-24 | 2001-06-04 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
DK1255536T3 (da) * | 1999-12-22 | 2006-10-30 | Sugen Inc | Indolinonderivater til modulation af c-kit-tyrosinproteinkinase |
US6573293B2 (en) * | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
TWI270545B (en) * | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
-
2003
- 2003-11-13 AR ARP030104194A patent/AR042042A1/es unknown
- 2003-11-14 GT GT200300245A patent/GT200300245A/es unknown
- 2003-11-14 PE PE2003001154A patent/PE20040835A1/es not_active Application Discontinuation
- 2003-11-14 CN CNB200380103225XA patent/CN100430060C/zh not_active Expired - Fee Related
- 2003-11-14 KR KR1020057008541A patent/KR20050086594A/ko not_active Application Discontinuation
- 2003-11-14 EP EP03783527A patent/EP1562600A4/en not_active Withdrawn
- 2003-11-14 CA CA002506308A patent/CA2506308A1/en not_active Abandoned
- 2003-11-14 PL PL376954A patent/PL376954A1/pl not_active Application Discontinuation
- 2003-11-14 CN CNA2008100814220A patent/CN101259131A/zh active Pending
- 2003-11-14 US US10/712,296 patent/US20040152759A1/en not_active Abandoned
- 2003-11-14 JP JP2004553729A patent/JP2006508981A/ja not_active Withdrawn
- 2003-11-14 TW TW092132030A patent/TW200418837A/zh unknown
- 2003-11-14 AU AU2003290943A patent/AU2003290943A1/en not_active Abandoned
- 2003-11-14 PA PA20038588601A patent/PA8588601A1/es unknown
- 2003-11-14 RU RU2005118417/14A patent/RU2342140C2/ru not_active IP Right Cessation
- 2003-11-14 MX MXPA05005150A patent/MXPA05005150A/es unknown
- 2003-11-14 WO PCT/US2003/036526 patent/WO2004045523A2/en active Application Filing
- 2003-11-14 UY UY28081A patent/UY28081A1/es not_active Application Discontinuation
- 2003-11-14 BR BR0315630-3A patent/BR0315630A/pt not_active IP Right Cessation
- 2003-11-14 NL NL1024779A patent/NL1024779C2/nl not_active IP Right Cessation
-
2005
- 2005-05-11 CO CO05045078A patent/CO5700778A2/es not_active Application Discontinuation
- 2005-05-12 ZA ZA200503841A patent/ZA200503841B/en unknown
- 2005-05-27 NO NO20052578A patent/NO20052578L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2005118417A (ru) | 2006-01-20 |
TW200418837A (en) | 2004-10-01 |
EP1562600A4 (en) | 2008-06-25 |
KR20050086594A (ko) | 2005-08-30 |
WO2004045523A3 (en) | 2004-09-30 |
CN100430060C (zh) | 2008-11-05 |
CN101259131A (zh) | 2008-09-10 |
ZA200503841B (en) | 2006-09-27 |
NO20052578L (no) | 2005-05-27 |
NL1024779A1 (nl) | 2004-05-18 |
WO2004045523A2 (en) | 2004-06-03 |
CA2506308A1 (en) | 2004-06-03 |
UY28081A1 (es) | 2004-06-30 |
BR0315630A (pt) | 2005-08-23 |
MXPA05005150A (es) | 2005-07-22 |
US20040152759A1 (en) | 2004-08-05 |
EP1562600A2 (en) | 2005-08-17 |
RU2342140C2 (ru) | 2008-12-27 |
JP2006508981A (ja) | 2006-03-16 |
CN1711089A (zh) | 2005-12-21 |
GT200300245A (es) | 2004-06-23 |
AU2003290943A1 (en) | 2004-06-15 |
PA8588601A1 (es) | 2004-05-21 |
NL1024779C2 (nl) | 2004-11-09 |
PE20040835A1 (es) | 2004-11-18 |
AR042042A1 (es) | 2005-06-08 |
PL376954A1 (pl) | 2006-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5700778A2 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
PA8593001A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
CO5640118A2 (es) | 5,7-diaminopirazol[4,3-d]piridinas utiles en el tratamiento de la hipertension | |
PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
UY28150A1 (es) | Agentes terapeuticos | |
PE20060842A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
UY29177A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos | |
PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
PE20080928A1 (es) | Derivados de anilinopiperazina como inhibidores de proteina quinasa | |
PE20080067A1 (es) | DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR) | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
ECSP088820A (es) | Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p. | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
PE20040197A1 (es) | Pirazolopiridinas sustituidas con carbamato | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
PE20020062A1 (es) | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a | |
PE20090511A1 (es) | Imidazopiridinonas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |